Replies to post #10167 on Arch Therapeutics Inc (ARTH)

[Polyphemus]

10Q SEC statement highlights - today
3 mo revenue $4,696 (now 2 years post US FDA clearance)
SG&A expenses grow to $1.2M - 41% increase
Cash on hand - $1M
Current liabilities - $749K, 83% increase
ACCUMULATED DEFICIT - $51.3M (wow)